Home
Healthcare
Summary
Agilent Technologies (A) is a moderate-conviction SELL at $173.01: 34.1x trailing GAAP earnings leaves insufficient risk-adjusted upside despite improving fundamentals.
My November 2029 scenarios imply $92 bear, $161 base and $247 bull outcomes; the base case delivers approximately −1.7% annualized including dividends.
A’s installed base supports recurring revenue and attractive margins, but cyclical equipment demand and acquisition execution remain important risks.
I would sell the position rather than await November 23 earnings, then reassess fiscal 2027 demand, margins, cash flow and pathology integration.
Getty Images
SELL (MODERATE Confidence)
As of market close (4:00 p.m. Eastern) on November 12, 2026, Agilent Technologies ( NYSE: A ) shares last traded at $173.01.…